Stockreport

Kyverna Therapeutics: 'Strong Buy' On Additional POC Of Miv-Cel In Myasthenia Gravis [Seeking Alpha]

Kyverna Therapeutics, Inc.  (KYTX) 
PDF Miv-cel achieved statistically significant endpoints in SPS and demonstrated deep, durable responses in gMG, with 100% of patients off chronic immunosuppression at 24 w [Read more]